製品の概要

  • 製品名Anti-Nmnat1 antibody [2642C5a]
    Nmnat1 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [2642C5a] to Nmnat1
  • アプリケーション適用あり: Dot blot, WBmore details
  • 種交差性
    交差種: Recombinant Fragment
    交差が予測される動物種: Human
  • 免疫原

    Recombinant fragment: TVVKGIISPV GDAYKKKGLI PAYHRVIMAE LATKNSKWVE VDTWESLQKE WKETLKVLRH HQEKLEASDC DHQQNSPTLE RPGRKRKWTE TQDSSQKKSL EPKTKAVP, corresponding to internal sequence amino acids 42-149 of Human Nmnat1

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab84855 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Dot blot Use at an assay dependent dilution.
WB Use at an assay dependent dilution. Predicted molecular weight: 32 kDa.

ターゲット情報

  • 機能Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults.
  • 組織特異性Widely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
  • パスウェイCofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
    Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.
  • 関連疾患Leber congenital amaurosis 9
  • 配列類似性Belongs to the eukaryotic NMN adenylyltransferase family.
  • 細胞内局在Nucleus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • EC 2.7.7.1 antibody
    • LCA9 antibody
    • Leber's congenital amaurosis 9 antibody
    • NaMN adenylyltransferase 1 antibody
    • nicotinamide nucleotide adenylyltransferase 1 antibody
    • Nicotinamide-nucleotide adenylyltransferase 1 antibody
    • Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 antibody
    • nicotinate nucleotide adenylyltransferase 1 antibody
    • Nicotinate-nucleotide adenylyltransferase 1 antibody
    • NMN adenylyltransferase 1 antibody
    • NMN/NaMN adenylyltransferase 1 antibody
    • NMNA1_HUMAN antibody
    • Nmnat 1 antibody
    • Nmnat1 antibody
    • OTTHUMP00000001731 antibody
    • OTTHUMP00000001732 antibody
    • OTTHUMP00000035892 antibody
    • PNAT 1 antibody
    • PNAT1 antibody
    • pyridine nucleotide adenylyltransferase 1 antibody
    see all

Anti-Nmnat1 antibody [2642C5a] 画像

Anti-Nmnat1 antibody [2642C5a] (ab84855) 使用論文

ab84855 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab84855.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"